Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle China JV Backs Nutritional And Rx Botanical Development

This article was originally published in The Tan Sheet

Executive Summary

Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.

You may also be interested in...



Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

Post Pumps Up Nutrition Activity With Nestle’s PowerBar, Musashi Brands

The cereal giant is bulking up its Active Nutrition Group and targeting annualized revenues of $550 million in the nutrition and weight loss sector. Post also continues diversifying its revenues with the deal.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel